Plain-English translation of NCT07424833 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called in people whose blood cancers—such as certain types of leukemia and lymphoma—have stopped responding to standard treatments. The study has two parts: first, researchers will find the right dose by gradually increasing it and watching for side effects; then, they will give that dose to more patients to confirm it works safely and effectively. The medication is taken by mouth, once a day.
Many people with relapsed or refractory blood cancers run out of treatment options after their cancer stops responding to standard therapies. This medication may offer a new option for patients who have already tried at least two other treatment approaches and have nowhere else to turn.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once daily in 28-day cycles. In the first part of the trial, you may be among the first patients to receive a starting dose, with doses adjusted based on safety; in the second part, you will be assigned to one of several dose groups to further test safety and effectiveness. Throughout the trial, you will have regular blood tests and check-ins to monitor how you are tolerating the treatment and whether your cancer is responding.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States